Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lavoltidine · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Lavoltidine | DRUG | - |
Inclusion Criteria: * Healthy male, from 18-55 years * Have BMI from 19-30 kg/m2 * do not present with abnormal clinical lab findings * are able to tolerate a nasogastric pH electrode. Exclusion Criteria: * Helicobacter-positive on a C13 urea breath test * have a baseline median 24-hour gastric p...
Lavoltidine is an investigational small molecule being studied for the treatment of Gastroesophageal Reflux Disease (GERD). It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being evaluated for its effect on gastric pH in patients with GERD.
Lavoltidine is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for Gastroesophageal Reflux Disease.
Lavoltidine is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains in early-stage clinical development for Gastroesophageal Reflux Disease.
Lavoltidine has one completed Phase 1 clinical trial registered under NCT00551473. This open-label, uncontrolled study evaluated the effect of once-daily administration of Lavoltidine 40 mg on 24-hour gastric pH on days 1, 2, and 7 in 18 healthy male volunteers in Australia.
Lavoltidine is a small molecule developed for Gastroesophageal Reflux Disease. Its specific molecular target has not been disclosed in available information. The drug is being studied for its ability to affect gastric pH, which is relevant to managing acid reflux symptoms.